Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228–1235.
Agid O, Potkin S, Remington G, Kapur S, Watsky E, Vanderburg D, Siu C (2010). Meta-analysis of placebo response in antipsychotic trials. APA Annual Meeting, New Orleans, May 2010.
Beasley CM Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996 a). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berlin) 124, 159–167.
Beasley CM Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996 b). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111–123.
Garver DL, Holcomb JA, Christensen JD (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 61, 964–972; quiz 973.
Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry 162, 939–946.
Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230–240.
Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 1543–1549.
Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR (2006). Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31, 2318–2325.
Levine SZ, Rabinowitz J (2008). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624–632.
Muthén B, Brown HC (2009). Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine 28, 3363–3385.
Muthén B, Brown CH, Leuchter A, Hunter A (in press). General approaches to analysis of course: applying growth mixture modeling to randomized trials of depression medication. In Causality and Psychopathology: Finding the Determinants of Disorders and their Cures (ed. Shrout P. E.). American Psychiatric Publishing: Washington, DC.
Muthén B, Brown CH, Masyn K, Jo B, Khoo ST, Yang CC, Wang CP, Kellam S, Carlin J, Liao J (2002). General growth mixture modeling for randomized preventive interventions. Biostatistics (Oxford, England) 3, 459–475.
Muthén B, Muthén L (2007). Mplus: Statistical Analysis with Latent Variables: User's Guide, 5th edn. Muthén and Muthén: Los Angeles, CA.
Muthén B, Shedden K (1999). Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55, 463–469.
Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799–812.
Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984). Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 41, 782–786.
Rothschild R, Quitkin FM (1992). Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychotherapy and Psychosomatics 58, 170–177.
Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A (2007). Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry 68, 1195–1205.
Stassen HH, Delini-Stula A, Angst J (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology 3, 127–135.
Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives General Psychiatry 55, 334–343.